Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma-Reference-Cited by-同舟云学术

Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma

Published:2010-08 Issue:8 Volume:20 Page:863-871
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Capp Clarissa¹,Wajner Simone Magagnin¹,Siqueira Débora Rodrigues¹,Brasil Beatriz Assis²,Meurer Luise²³,Maia Ana Luiza¹

Affiliation:

1. Thyroid Section, Endocrine Division, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

2. Pathology Department, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

3. Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2009.0417

Reference48 articles.

1. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop

2. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis

3. Tumor Angiogenesis

4. Expression of c-Kit, Flk-1, and Flk-2 Receptors in Benign and Malignant Tumors of Follicular Epithelial Origin

5. Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Insights into Hybrid Tumors: Exploring the Heterogeneity in Plexiform Ameloblastoma;Seminars in Diagnostic Pathology;2024-09

2. Adaptive resistance of tumor cells to anti-vascular endothelial growth factor therapy: A reversible phenomenon;Cytokine;2024-08

3. Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions;European Journal of Medicinal Chemistry;2024-06

4. Direct antitumor activity of bevacizumab: an overlooked mechanism?;Frontiers in Pharmacology;2024-04-23

5. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions;Annales d'Endocrinologie;2024-04